Skip to main content
Erschienen in: Urolithiasis 2/2007

01.04.2007 | Original Paper

Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function

verfasst von: Markus Jaggi, Yasushi Nakagawa, Ljerka Zipperle, Bernhard Hess

Erschienen in: Urolithiasis | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Tamm-Horsfall protein (THP) powerfully inhibits calcium oxalate crystal aggregation, but structurally abnormal THPs from recurrent calcium stone formers may promote crystal aggregation. Therefore, increased urinary excretion of abnormal THP might be of relevance in nephrolithiasis. We studied 44 recurrent idiopathic calcium stone formers with a positive family history of stone disease (RCSFfam) and 34 age- and sex-matched healthy controls (C). Twenty-four-hour urinary THP excretion was measured by enzyme linked immunosorbent assay. Structural properties of individually purified THPs were obtained from analysis of elution patterns from a Sepharose 4B column. Sialic acid (SA) contents of native whole 24-h urines, crude salt precipitates of native urines and individually purified THPs were measured. THP function was studied by measuring inhibition of CaOx crystal aggregation in vitro (pH 5.7, 200 mM sodium chloride). Twenty-four-hour urine excretion of THP was higher in RCSFfam (44.0 ± 4.0 mg/day) than in C (30.9 ± 2.2 mg/day, P = 0.015). Upon salt precipitation and lyophilization, elution from a Sepharose 4B column revealed one major peak (peak A, cross-reacting with polyclonal anti-THP antibody) and a second minor peak (peak B, not cross-reacting). THPs from RCSFfam eluted later than those from C (P = 0.021), and maximum width of THP peaks was higher in RCSFfam than in C (P = 0.024). SA content was higher in specimens from RCSFfam than from C, in native 24-h urines (207.5 ± 20.4 mg vs. 135.2 ± 16.1 mg, P = 0.013) as well as in crude salt precipitates of 24-h urines (10.4 ± 0.5 mg vs. 7.4 ± 0.9 mg, P = 0.002) and in purified THPs (75.3 ± 9.3 μg/mg vs. 48.8 ± 9.8 μg/mg THP, P = 0.043). Finally, inhibition of calcium oxalate monohydrate crystal aggregation by 40 mg/L of THP was lower in RCSFfam (6.1 ± 5.5%, range −62.0 to +84.2%) than in C (24.9 ± 6.0%, range −39.8 to +82.7%), P = 0.022, and only 25 out of 44 (57%) THPs from RCSFfam were inhibitory (positive inhibition value) vs. 25 out of 34 (74%) THPs from C, P < 0.05. In conclusion, severely recurrent calcium stone formers with a positive family history excrete more THP than healthy controls, and their THP molecules elute later from an analytical column and contain more SA. Such increasingly aggregated THP molecules predispose to exaggerated calcium oxalate crystal aggregation, an important prerequisite for urinary stone formation.
Literatur
1.
Zurück zum Zitat Kumar S, Muchmore A (1990) Tamm-Horsfall protein—Uromodulin (1950–1990). Kidney Int 37:1395–1401PubMed Kumar S, Muchmore A (1990) Tamm-Horsfall protein—Uromodulin (1950–1990). Kidney Int 37:1395–1401PubMed
2.
Zurück zum Zitat Serrafini-Cessi F, Malagolini N, Cavallone D (2003) Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 42:658–676CrossRef Serrafini-Cessi F, Malagolini N, Cavallone D (2003) Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 42:658–676CrossRef
3.
Zurück zum Zitat Pak J, Pu Y, Zjang Z-T, Hasty DL, Wu X-R (2001) Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem 276:9924–9930PubMedCrossRef Pak J, Pu Y, Zjang Z-T, Hasty DL, Wu X-R (2001) Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem 276:9924–9930PubMedCrossRef
4.
Zurück zum Zitat Bates JM, Raffi HM, Prasadan K, Mascarenhas R, Laszik Z, Maeda N, Hultgren SJ, Kumar S (2004) Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int 65:791–797PubMedCrossRef Bates JM, Raffi HM, Prasadan K, Mascarenhas R, Laszik Z, Maeda N, Hultgren SJ, Kumar S (2004) Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int 65:791–797PubMedCrossRef
5.
Zurück zum Zitat Wimmer T, Cohen G, Saemann MD, Hörl WH (2004) Effects of Tamm-Horsfall protein on polymorphonuclear leukocyte function. Nephrol Dial Transplant 19:2192–2197PubMedCrossRef Wimmer T, Cohen G, Saemann MD, Hörl WH (2004) Effects of Tamm-Horsfall protein on polymorphonuclear leukocyte function. Nephrol Dial Transplant 19:2192–2197PubMedCrossRef
6.
Zurück zum Zitat Mo L, Huang H-Y, Zhu X-H, Shapiro E, Hasty DL, Wu X-R (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166PubMedCrossRef Mo L, Huang H-Y, Zhu X-H, Shapiro E, Hasty DL, Wu X-R (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166PubMedCrossRef
7.
Zurück zum Zitat Hess B, Kok DJ (1996) Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management, Chap. 1. Lippincott-Raven Publishers, Philadelphia Hess B, Kok DJ (1996) Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management, Chap. 1. Lippincott-Raven Publishers, Philadelphia
8.
Zurück zum Zitat Fleisch H (1987) Inhibitors and promoters of stone formation. Kidney Int 13:361–371 Fleisch H (1987) Inhibitors and promoters of stone formation. Kidney Int 13:361–371
9.
Zurück zum Zitat Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46:847–854PubMed Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46:847–854PubMed
10.
Zurück zum Zitat Khan SR (1997) Tubular surface events during nephrolithiasis. Curr Opin Urol 7:240–247CrossRef Khan SR (1997) Tubular surface events during nephrolithiasis. Curr Opin Urol 7:240–247CrossRef
11.
Zurück zum Zitat Scurr DS, Robertson WG (1986) Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. J Urol 136:128–131PubMed Scurr DS, Robertson WG (1986) Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. J Urol 136:128–131PubMed
12.
Zurück zum Zitat Hess B (1994) Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner Electrolyte Metab 20:393–398PubMed Hess B (1994) Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner Electrolyte Metab 20:393–398PubMed
13.
Zurück zum Zitat Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257:F99–F106PubMed Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257:F99–F106PubMed
14.
Zurück zum Zitat Hess B, Zipperle L, Jaeger Ph (1993) Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265:F784–F791PubMed Hess B, Zipperle L, Jaeger Ph (1993) Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265:F784–F791PubMed
15.
Zurück zum Zitat Hess B, Nakagawa Y, Parks JH, Coe FL (1991) Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260:F569–F578PubMed Hess B, Nakagawa Y, Parks JH, Coe FL (1991) Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260:F569–F578PubMed
16.
Zurück zum Zitat Knörle R, Schnierle P, Koch A, Buchholz N-P, Hering F, Seiler H, Ackermann T, Rutishauser G (1994) Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier-transform infrared spectrometry. Clin Chem 40:1739–1743PubMed Knörle R, Schnierle P, Koch A, Buchholz N-P, Hering F, Seiler H, Ackermann T, Rutishauser G (1994) Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier-transform infrared spectrometry. Clin Chem 40:1739–1743PubMed
17.
Zurück zum Zitat Glauser A, Hochreiter W, Jaeger Ph, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 14:1580–1587CrossRef Glauser A, Hochreiter W, Jaeger Ph, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 14:1580–1587CrossRef
18.
Zurück zum Zitat Reinhart HH, Obedeanu N, Walz D, Sobel JD (1989). A new ELISA method for the rapid quantification of Tamm-Horsfall protein in urine. Am J Pathol 92:199–205 Reinhart HH, Obedeanu N, Walz D, Sobel JD (1989). A new ELISA method for the rapid quantification of Tamm-Horsfall protein in urine. Am J Pathol 92:199–205
19.
Zurück zum Zitat Fletcher AP, Neuberger A, Ratcliffe WA (1970) Tamm-Horsfall urinary glycoprotein: the chemical composition. Biochem J 120:417–424PubMed Fletcher AP, Neuberger A, Ratcliffe WA (1970) Tamm-Horsfall urinary glycoprotein: the chemical composition. Biochem J 120:417–424PubMed
20.
Zurück zum Zitat Aminoff D (1961) Method for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem J 81:384–392PubMed Aminoff D (1961) Method for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem J 81:384–392PubMed
21.
Zurück zum Zitat Bichler KH, Kirchner Ch, Ideler V (1976) Uromucoid excretion in normal individuals and stone formers. Br J Urol 47:733–738CrossRef Bichler KH, Kirchner Ch, Ideler V (1976) Uromucoid excretion in normal individuals and stone formers. Br J Urol 47:733–738CrossRef
22.
Zurück zum Zitat Samuell CT (1979) Uromucoid excretion in normal subjects, calcium stone formers and in patients with chronic renal failure. Urol Res 7:5–12PubMedCrossRef Samuell CT (1979) Uromucoid excretion in normal subjects, calcium stone formers and in patients with chronic renal failure. Urol Res 7:5–12PubMedCrossRef
23.
Zurück zum Zitat Thornley C, Dawnay A, Cattell WR (1985) Human Tamm-Horsfall glycoprotein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay. Clin Sci 68:529–535PubMed Thornley C, Dawnay A, Cattell WR (1985) Human Tamm-Horsfall glycoprotein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay. Clin Sci 68:529–535PubMed
24.
Zurück zum Zitat Erwin DT, Kok DJ, Alam J, et al (1994) Calcium oxalate stone agglomeration reflects stone forming activity: citrate inhibition depends on macromolecules larger than 30 kilodaltons. Am J Kidney Dis 24:893–900PubMed Erwin DT, Kok DJ, Alam J, et al (1994) Calcium oxalate stone agglomeration reflects stone forming activity: citrate inhibition depends on macromolecules larger than 30 kilodaltons. Am J Kidney Dis 24:893–900PubMed
25.
Zurück zum Zitat Romero MC, Nocera S, Nesse AB (1997) Decreased Tamm-Horsfall protein in lithiasic patients. Clin Biochem 30:63–67PubMedCrossRef Romero MC, Nocera S, Nesse AB (1997) Decreased Tamm-Horsfall protein in lithiasic patients. Clin Biochem 30:63–67PubMedCrossRef
26.
Zurück zum Zitat Ganter K, Bongartz D, Hesse A (1999) Tamm-Horsfall protein excretion and its relation to citrate in urine of stone-forming patients. Urology 53:492–495PubMedCrossRef Ganter K, Bongartz D, Hesse A (1999) Tamm-Horsfall protein excretion and its relation to citrate in urine of stone-forming patients. Urology 53:492–495PubMedCrossRef
27.
Zurück zum Zitat Bichler KH, Mittermüller B, Strohmaier WL, Feil G, Eipper E (1999) Excretion of Tamm-Horsfall protein in patients with uric acid stones. Urol Int 62:87–92PubMedCrossRef Bichler KH, Mittermüller B, Strohmaier WL, Feil G, Eipper E (1999) Excretion of Tamm-Horsfall protein in patients with uric acid stones. Urol Int 62:87–92PubMedCrossRef
28.
Zurück zum Zitat Sumitra K, Pragasam V, Sakthivel R, Kalaiselvi P, Varalakshmi P (2005) Beneficial effects of vitamin E supplementation on the biochemical and kinetic properties of Tamm-Horsfall glycoprotein in hypertensive and hyperoxaluric subjects. Nephrol Dial Transplant 20:1407–1415PubMedCrossRef Sumitra K, Pragasam V, Sakthivel R, Kalaiselvi P, Varalakshmi P (2005) Beneficial effects of vitamin E supplementation on the biochemical and kinetic properties of Tamm-Horsfall glycoprotein in hypertensive and hyperoxaluric subjects. Nephrol Dial Transplant 20:1407–1415PubMedCrossRef
29.
Zurück zum Zitat Khan SR (2004) Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol 98:e55–e60PubMedCrossRef Khan SR (2004) Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol 98:e55–e60PubMedCrossRef
30.
Metadaten
Titel
Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function
verfasst von
Markus Jaggi
Yasushi Nakagawa
Ljerka Zipperle
Bernhard Hess
Publikationsdatum
01.04.2007
Verlag
Springer-Verlag
Erschienen in
Urolithiasis / Ausgabe 2/2007
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-007-0083-7

Weitere Artikel der Ausgabe 2/2007

Urolithiasis 2/2007 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.